Company Filing History:
1 out of 94 
1 out of 93 
Years Active: 2011
Title: Florence Lefranc: Innovator in Cancer Treatment
Introduction
Florence Lefranc is a notable inventor based in Sint-Pieters-Leeuw, Belgium. She has made significant contributions to the field of cancer treatment through her innovative research and development of RNAi-based approaches. Her work focuses on targeting galectin-1 to improve therapeutic outcomes for various types of cancer.
Latest Patents
Florence Lefranc holds a patent for the "Use of a galectin-1-targeted RNAi-based approach for the treatment of cancer." This invention relates to an RNAi molecule designed to reduce the expression of galectin-1, utilizing sequences from SEQ ID NOs: 1-33, with a preference for SEQ ID NOs: 2, 3, or 4. The patent outlines its application as a medicament for treating or delaying the progression of cancers such as glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer, and non-Hodgkin's lymphoma. Additionally, it includes methods for reducing tumor cell migration and enhancing the efficacy of various cancer therapies.
Career Highlights
Florence has worked with prestigious institutions, including Université Libre de Bruxelles and Université Catholique de Louvain. Her research has been pivotal in advancing cancer treatment methodologies, particularly through the innovative use of RNA interference technology.
Collaborations
Florence has collaborated with esteemed colleagues such as Isabelle Camby and Patrick Henriet, contributing to a rich environment of research and innovation in cancer therapies.
Conclusion
Florence Lefranc's work exemplifies the intersection of innovation and healthcare, particularly in the fight against cancer. Her contributions through her patent and collaborations highlight her commitment to improving patient outcomes and advancing medical science.